Safety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV-TARGET

Journal of Hepatology

Volumn 62, Issue 2, 2015, Pages 286-293

  Gordon, Stuart C ^a   Muir, Andrew J ^b   Lim, Joseph K ^c   Pearlman, Brian ^d   Argo, Curtis K ^e   Ramani, Ananthakrishnan ^f   Maliakkal, Benedict ^g   Alam, Imtiaz ^h   Stewart, Thomas G ⁱ   Vainorius, Monika ⁱ   Peter, Joy ^j   Nelson, David R ^j   Fried, Michael W ⁱ   Reddy, K Rajender ^k  

^a HENRY FORD HOSPITAL   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ATLANTA MEDICAL CENTER   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f Division of Orthopaedic Surgery   (United States)

^g STRONG MEMORIAL HOSPITAL   (United States)

^h Austin Hepatitis Center   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA   (United States)

^j UNIVERSITY OF FLORIDA   (United States)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

Anaemia; Boceprevir; Cirrhosis; Hepatic decompensation; Hepatitis C; Telaprevir

Indexed keywords

ALBUMIN; BOCEPREVIR; CREATININE; ERYTHROPOIETIN; HEMOGLOBIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; TELAPREVIR; ANTIVIRUS AGENT; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE; VIRUS DNA;

ADULT; AGED; ANEMIA; ANORECTAL DISEASE; ARTICLE; BLOOD TRANSFUSION; DEATH; DECOMPENSATED LIVER CIRRHOSIS; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; FEMALE; FOLLOW UP; GENOTYPE; HEALTH CARE QUALITY; HEART INFARCTION; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION; LIVER CIRRHOSIS; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PREDICTOR VARIABLE; PRESCRIPTION; PRIORITY JOURNAL; RASH; SEPSIS; THROMBOCYTE; UNITED STATES; ADOLESCENT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DOSE RESPONSE; DRUG COMBINATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROLINE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84922268018     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.08.052     Document Type: Article

References (12)

1. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-716.
2. Poordad F, McCone Jr J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
3. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
4. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
5. Barritt AS, Fried MW. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. Gastroenterology 2012; 142: 1314-1323.
6. Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013; 59: 434-441.
7. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
8. Colombo M, Fernández I, Abdurakhmanov D, Ferreira PA, Strasser SI, Urbanek P, et al. Safety and on-treatment efficacy of telaprevir: The early access programme for patients with advanced hepatitis C. Gut 2014; 63: 1150-1158.
9. Maasoumy B, Port K, Markova AA, Serrano BC, Rogalska-Taranta M, Sollik L, et al. Eligibility and safety of triple therapy for hepatitis C: Lessons learned from the first experience in a real world setting. PLoS One 2013; 8: E55285.
10. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
11. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024.
12. Afdhal NH, Reau N, Everson GT, Morelli G, Lok AS, Kenneth E, et al. Safety and efficacy of telaprevir (TVR) or boceprevir (BOC) in Patients with cirrhosis: Interim results of a longitudinal, observational study. Hepatology 2013; 58: 1103A-1104A.